Your session is about to expire
← Back to Search
Dual-Tracer PET Scans for Prostate Cancer
N/A
Recruiting
Led By Jeffrey A Yap, PhD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 days
Awards & highlights
Study Summary
This trial tests new imaging techniques to help understand diseases better.
Who is the study for?
Adults with measurable prostate cancer or neuroendocrine tumors, willing to undergo PET/CT scans and have their records reviewed for 24 months. Women of childbearing potential must test negative for pregnancy. Exclusions include exceeding weight limits, recent participation in other clinical studies, known allergies to study materials, and claustrophobia.Check my eligibility
What is being tested?
The trial is testing four different single-tracer PET/CT exams (FDG, Cu64-DOTATATE, Ga68-DOTATATE, PSMA) on patients with prostate cancer or neuroendocrine tumors. The goal is to gather data for developing dual-tracer imaging techniques.See study design
What are the potential side effects?
Potential side effects may include reactions to the tracers used during the PET/CT exams such as allergic reactions or hypersensitivity. Discomfort from lying flat during scanning could also occur.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Completion of two PET/CT scans per patient as dictated by assigned arm
Trial Design
3Treatment groups
Experimental Treatment
Group I: Arm 3Experimental Treatment2 Interventions
Single-Tracer FDG PET/CT exam + Single-Tracer PSMA (prostate-specific membrane antigen) PET/CT exam
Group II: Arm 2Experimental Treatment2 Interventions
Single-Tracer FDG PET/CT exam + Single-Tracer Ga68-DOTATATE PET/CT exam
Group III: Arm 1Experimental Treatment2 Interventions
Single-Tracer FDG (F18 Fluorodeoxyglucose) PET/CT exam + Single-Tracer Cu64-DOTATATE PET/CT
Find a Location
Who is running the clinical trial?
University of UtahLead Sponsor
1,099 Previous Clinical Trials
1,778,639 Total Patients Enrolled
7 Trials studying Prostate Cancer
5,299 Patients Enrolled for Prostate Cancer
MultiFunctional Imaging LLCUNKNOWN
National Cancer Institute (NCI)NIH
13,664 Previous Clinical Trials
40,926,083 Total Patients Enrolled
560 Trials studying Prostate Cancer
507,045 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have never received somatostatin receptor therapy before joining.I need anesthesia for PET/CT scans.I am willing to have two PET/CT scans within two weeks apart.I am 18 years old or older.I can lie flat on my back for up to an hour.I will take a pregnancy test if I'm not postmenopausal or surgically sterile before PET scans.I have a neuroendocrine tumor that may show up on a special PET scan.I might have prostate cancer with possible spread or recurrence, indicated by high PSA levels.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 1
- Group 2: Arm 2
- Group 3: Arm 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the estimated recruitment rate for this investigation?
"Affirmative. According to the clinicaltrials.gov database, this investigation is presently recruiting participants and was initially published on December 13th 2022. Its last update occurred on December 27th 2022, in search of 50 volunteers from a single locale."
Answered by AI
Are patients still able to enroll in this trial?
"Affirmative. According to details found on clinicaltrials.gov, enrollment for this trial is still going and began on December 13th 2022. It was last modified a fortnight later. This study necessitates 50 patients at one medical facility."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger